ES2132121T3 - Procedimiento para la purificacion de inhibidores de la hmg-coa reductasa. - Google Patents

Procedimiento para la purificacion de inhibidores de la hmg-coa reductasa.

Info

Publication number
ES2132121T3
ES2132121T3 ES92908427T ES92908427T ES2132121T3 ES 2132121 T3 ES2132121 T3 ES 2132121T3 ES 92908427 T ES92908427 T ES 92908427T ES 92908427 T ES92908427 T ES 92908427T ES 2132121 T3 ES2132121 T3 ES 2132121T3
Authority
ES
Spain
Prior art keywords
hmg
purification
inhibitors
procedure
coa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92908427T
Other languages
English (en)
Inventor
Peter N Haytko
Arthur S Wildman Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24683910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2132121(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2132121T3 publication Critical patent/ES2132121T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/322—Normal bonded phase
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

UN PROCESO PARA LA PURIFICACION DE UN INHIBIDOR DE REDUCTASA HMG-COA QUE EMPLEA UNA CROMATOGRAFIA LIQUIDA DE ALTA PRESTACION PREPARATORIA ASI COMO UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL INHIBIDOR DE REDUCTASA HMG-COA Y PORTADOR FARMACEUTICAMENTE ACEPTABLE.
ES92908427T 1991-03-13 1992-03-09 Procedimiento para la purificacion de inhibidores de la hmg-coa reductasa. Expired - Lifetime ES2132121T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/668,831 US5202029A (en) 1991-03-13 1991-03-13 Process for purification of hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
ES2132121T3 true ES2132121T3 (es) 1999-08-16

Family

ID=24683910

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92908427T Expired - Lifetime ES2132121T3 (es) 1991-03-13 1992-03-09 Procedimiento para la purificacion de inhibidores de la hmg-coa reductasa.

Country Status (9)

Country Link
US (1) US5202029A (es)
EP (1) EP0578723B1 (es)
JP (1) JPH06506210A (es)
AT (1) ATE180986T1 (es)
CA (1) CA2104232A1 (es)
DE (1) DE69229393D1 (es)
ES (1) ES2132121T3 (es)
GR (1) GR3030446T3 (es)
WO (1) WO1992016276A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308479A (en) * 1989-05-26 1994-05-03 Isamu Iwai Sewage disposal apparatus employing circulating filter media
DE4414537A1 (de) * 1994-04-26 1995-11-02 Klinge Co Chem Pharm Fab Kombinationspräparate mit einem Gehalt an einem p-Oxybenzoesäurederivat und einem HMG-CoA-Reduktase-Hemmer
SI9800046A (sl) * 1998-02-18 1999-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
US7141602B2 (en) * 1998-09-18 2006-11-28 Lek Pharmaceuticals D.D. Process for obtaining HMG-CoA reductase inhibitors of high purity
US6380401B1 (en) 1999-10-27 2002-04-30 Merck & Co., Inc. Lactonization process
WO2001039768A1 (en) 1999-11-30 2001-06-07 Biogal Gyogyszergyar Rt Process for recovering statin compounds from a fermentation broth
HK1049441A1 (zh) * 1999-12-14 2003-05-16 Biogal Gyogyszergyar Rt 普伐他丁钠的崭新形式
WO2001062949A1 (en) 2000-02-24 2001-08-30 Biogal Gyogyszergyar Rt Method of purifying a fermentation broth
AU4183301A (en) * 2000-03-03 2001-09-17 Biogal Gyogyszergyar A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
EP1192963A4 (en) * 2000-04-05 2004-08-25 Toray Industries ADSORBENTS FOR PROTEINS OF THE HIGH MOBILITY PROTEIN AND PILLAR GROUP FOR CLEANING BODY LIQUIDS
US6936731B2 (en) * 2000-10-05 2005-08-30 TEVA Gyógyszergyár Részvénytársaság Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
HRP20030347A2 (en) * 2000-10-05 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US20050215636A1 (en) * 2000-10-05 2005-09-29 Vilmos Keri Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
JP3236282B1 (ja) 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
EP1790634A3 (en) * 2003-06-18 2007-06-13 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal form and processes for preparing it
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
PL1641447T3 (pl) 2003-11-24 2009-04-30 Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag Sposób oczyszczania prawastatyny
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
ES2239533B1 (es) * 2004-03-01 2006-12-16 Ercros Industrial, S.A. Procedimiento para la obtencion de compactina.
WO2006035295A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for the purification of lovastatin
TWI345562B (en) 2005-02-22 2011-07-21 Teva Pharma Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
WO2009078033A2 (en) * 2007-12-18 2009-06-25 Themis Medicare Limited Isolation and recovery of simvastatin in lactone form or in the form of an acid salt from the harvested fermentation broth
US9078849B2 (en) 2009-04-08 2015-07-14 Nanyang Polytechnic Plant extract comprising statins and preparation techniques and uses thereof
CN102043030A (zh) * 2009-10-22 2011-05-04 北京万全阳光医学技术有限公司 一种用高效液相色谱法测定烟酸辛伐他汀缓释片有关物质的方法
EP2590722A4 (en) * 2010-07-07 2015-06-24 Ironstone Separations Inc TIMING PROCEDURE
EP2597092A1 (en) 2011-11-24 2013-05-29 Sterling Biotech Limited A process for purification of lovastatin
CN112657231B (zh) * 2020-12-24 2022-06-10 西安蓝晓科技新材料股份有限公司 一种三七总皂苷的提纯工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS58140024A (ja) * 1982-02-15 1983-08-19 Eisai Co Ltd セクレチンの精製方法
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
US4719229A (en) * 1987-05-13 1988-01-12 Merck & Co., Inc. Antihypercholesterolemic agents
US4778600A (en) * 1987-06-17 1988-10-18 Dow Corning Corporation Liquid chromatography dual zone packing materials
US4997755A (en) * 1988-04-15 1991-03-05 Merck & Co., Inc. HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
US5099035A (en) * 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5102911A (en) * 1989-06-09 1992-04-07 Merck & Co, Inc. 4-Substituted HMG-CoA reductase inhibitors
US4997849A (en) * 1989-06-23 1991-03-05 Merck & Co., Inc. Microbial transformation of simvastatin
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US5089523A (en) * 1990-05-11 1992-02-18 E. R. Squibb & Sons, Inc. Fluorinated derivatives of mevinic acids

Also Published As

Publication number Publication date
CA2104232A1 (en) 1992-09-14
WO1992016276A1 (en) 1992-10-01
GR3030446T3 (en) 1999-09-30
US5202029A (en) 1993-04-13
JPH06506210A (ja) 1994-07-14
DE69229393D1 (de) 1999-07-15
EP0578723B1 (en) 1999-06-09
EP0578723A1 (en) 1994-01-19
EP0578723A4 (en) 1994-06-22
ATE180986T1 (de) 1999-06-15

Similar Documents

Publication Publication Date Title
EP0578723A4 (en) Process for purification of hmg-coa reductase inhibitors
BR9506535A (pt) Inibidores de metaloproteinases
TW269682B (es)
CO4780028A1 (es) Procedimiento para la preparacion de sildenafil
EA199800302A1 (ru) Способ получения дифторметана
BR9401952A (pt) União para conexão rápida estanque de tubulações
DK0788496T3 (da) Inhibitorer for syntese af apolipoprotein-B
ES2134910T3 (es) Sintesis de bisindolilmaleimidas.
PT545511E (pt) Processo para a preparacao de tetraazamacrociclos mono-n-substituidos
NO960168L (no) Fremgangsmåte for fremstilling av HIV-proteaseinhibitorer
DK624088A (da) Fremgangsmaade til kontinuerlig forgaering af carbonhydratholdige medier ved hjaelp af bakterier
DE69008277D1 (de) 7-Subsituierte HMG-CoA-Reduktase-Inhibitoren.
NO921806L (no) Fremgangsmaate ved hydrodesyklisering av gassolje
MX9302878A (es) Procedimiento para la preparacion de un diaminodiol substituido.
DE69301555D1 (de) Hochdruckverflüssiger
BR9104604A (pt) Dispositivo para expansao de gases liquefeitos
SV1997000031A (es) Nuevo procedimiento eficaz y de alta selectividad enantiomerica para la producccion de ciclopentano-beta- aminoacidos enantiomericamente puros. ref. lea 31688-sv
BR9104605A (pt) Dispositivo para expansao de gases liquefeitos
NO931875D0 (no) Anordning ved blendfri belysning av flater
NO923862D0 (no) Inhibitorer for hmg-coa-reduktase
KR940023763U (ko) 대상체의 위치 발견용 페이지 장치
ATE135352T1 (de) 3-keto-hmg-coa reduktase-inhibitoren
KR950011967U (ko) 자동차의 클러치 유격조정용 푸쉬로드(push rod)
KR950015443U (ko) 전자렌지용 고압 트랜스
NO932445D0 (no) Fremgangsmaate for resirkulering av brukt smoereolje

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 578723

Country of ref document: ES